Pharma Capital
EPIC: OPTI
Market: AIM
52-week High/Low: 90.00p / 59.00p
Sector: Health Care, Equipment & Services
Market Cap: 54.59M
Phone: +44 (0)7887 874 392
Address: Innovation Centre, Innovation Way, Heslington, York YO10 5DG.
Website: www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations which modulate the human microbiome and can be used as food ingredients, supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

OptiBiotix has developed a portfolio of intellectual property in and around this field of research, consisting of patents, trademarks and novel microbial strains. Further intellectual property is expected to be developed or acquired as opportunities arise from existing and future research and development.

OptiBiotix has been working with leading international key opinion leaders and entered into a research agreement with the University of Reading on 18 September 2012 to generate novel microbiome modulating compounds using reverse enzyme synthesis. All intellectual property arising from this research is owned by OptiBiotix.

OptiBiotix Health plc

www.optibiotix.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in OptiBiotix Health plc

OptiBiotix Health plc Snapshot

 

Welcome to Optibiotix Health PLC

Recent advances in cellular and molecular biology have led to a greater understanding of the strains and functions of bacteria that make up the human microbiome - the collective genome of the microbes in the body - providing greater insight into the role of microbial flora in human health.  An increasing number of scientific studies have now shown that our bacterial flora are influential in the development and aetiology of diseases as diverse as inflammatory bowel disease, autism, atherosclerosis, gastrointestinal cancers and metabolic diseases such as type 1 diabetes and obesity.

The healthy human microbiome contains at least 10,000 microbial species with some eight million different protein-encoding genes, 360 times more genes than the human genome. This metabolically active, rapidly renewable ecosystem makes up over 90% of the cells in the human body and contributes to host immunity, metabolism and  physiology. More importantly this vast and diverse microbial genome is easier to influence than the human genome. This creates the potential to diagnose, prevent or treat disease by modifying the organisms in or on the human  body. 

The prospect of modulating the human microbiome to prevent, manage, and treat human disease has led the human microbiome to be described as one of the most significant scientific breakthroughs of 2013 and one of the top 10 emerging technologies of 2014.

OptiBiotix®Health intends to exploit these recent scientific advances to develop a range of products which can modify the human microbiome and bring specific health benefits.  This will meet a large and growing consumer need for nutritional and effective health care products supported by scientific evidence and clinical studies.  With increasing scientific corroboration of health benefits from products which modify the human microbiome this sector has been predicted to become one of the world’s fastest growth areas in the next 10 years. 

Microbiome Research May Soon Pay Off Big

OptiBiotix’s CEO ‘ Stephen OHara said ‘This publication recognises that research into the human microbiome has given scientists the potential to change the microbiome and the potential this brings to prevent, manage, and treat many diseases.  OptiBiotix is leading this field and looks forward to bringing new products to market to help sufferers with common lifestyle diseases such as heart disease, obesity, and diabetes’.

http://www.nutraingredients.com/Research/Bill-Gates-Foundation-backs-microbiome-engineering-to-boost-infant-health 

Stephen OHara, OptiBiotix CEO said ‘ This new research funding recognises the role of microbiome engineering in human heath and brings new grant funding to support research into the many issues that face developing countries.  The increase in grant funding from the Gates Foundation and others will further support the development of microbiome applications to prevent, manage, and treat human disease’.  

Extreme weight loss surgery works, but is it thanks to the knife—or the microbes?

OptiBiotix’s CEO Stephen OHara said ‘ This is one of a series of recent scientific reports providing evidence for the role of microbial changes in weight loss following bariatric surgery and the ‘cure’ of type 2 diabetes. The implication being that rather than have bariatric (e.g gastric band) surgery you would simply change your microbiome to loose weight and/or ‘cure’ type 2 diabetes.   OptiBiotix is developing microbiome modulators which can change the microbial flora and this creates the potential to reduce weight without the risks and cost associated with surgery’.   

Human Microbiome Market worth $658 Million by 2023

OptiBiotix’s CEO Stephen OHara said ‘This report highlights the tremendous opportunity of the human microbiome with its growth potential being recognised by large corporate, food, health, and increasingly pharmaceutical companies. This creates multiple product and partnering opportunities for OptiBiotix across its two technology platforms. OptiBiotix is well placed to exploit the growing media, investor, and corporate interest in the microbiome and build a business with significant value for shareholders

Steven OHara comments on Daily Mail article referencing Statins

Stephen OHara, OptiBiotix’s CEO said: ‘Whilst this appears to be speculative reporting this article in the Mail reflects increasing concern about side affects from statins. Whilst many users will benefit from statins an increasing number are likely to look to for alternative treatment options.  There is growing interest in healthcare in the use of  agents which supplement existing treatment options in having mechanisms which work complementary to statins.  This creates the potential  to lower statin dosage, reduce cost, improve statin compliance and limit potential side effects.  This is likely to increase interest is products such as OptiBiotix’s cholesterol reducing microbial supplement’.

http://www.express.co.uk/life-style/health/639586/Statins-doubles-diabetes-study-drug

Stephen OHara, OptiBiotix’s CEO said: ‘This report in the Express is another article highlighting concerns from the side affects from statins.  This has created interest from healthcare providers in the use of  agents which replace or supplement existing treatment options: particularly where mechanisms of action work complementary to existing treatments.  OptiBiotix’s microbial strain has shown significant reduction in LDL cholesterol in clinical studies and has a mechanism of action complementary to statins.  This suggests combinational treatment may have the potential to lower statin dosage, reduce cost, and limit side effects whilst improving statin compliance’

http://www.dailymail.co.uk/health/article-4221424/The-real-reason-Leah-2-stone-stomach-bacteria.html 

Stephen OHara, OptiBiotix’s CEO said: ‘This news paper article reports on the role of the microbiome in weight loss. Whilst rather speculative it does reflect the growing scientific understanding on factors such as the microbiome which may be  influencing sustainable weight loss. The early evidence suggests that people with a greater microbial diversity  may be able to respond more quickly to dieting  and are more able to sustain weight loss than those with less microbial diversity.  People who have fast food diets tend to have a restricted microbial diversity and this study would suggest that losing and sustaining weight loss may be more difficult in these groups. GoFigure® products containing SlimBiome®, OptiBiotix’s patented formulation of ingredients developed by experts to support weight loss, includes a  prebiotic designed to enhance microbial diversity which this research suggests is likely to help people lose weight more quickly and sustain this weight loss. This creates the opportunity for easier and more sustainable weight loss than would be achieved with more traditional diets’.

Innovation Centre

Innovation Way

Heslington

York

YO10 5DG

 

Nominated Adviser

Cairn Financial Advisers LLP

61 Cheapside

London

EC2V 6AX

 

Solicitors to the Company as to English law

Turner Parkinson LLP

Hollins Chambers

64a Bridge Street

Manchester

M3 3BA

 

Reporting Accountants and Auditors

Jeffreys Henry LLP

5-7 Cranwood Street

London

EC1V 9EE

 

Financial Public Relations

Walbrook PR Ltd

4 Lombard Street

London

EC3V 9HD

Tel: 020 7933 8780

[email protected]

 

Broker

finnCap

60 New Broad Street,

London

EC2M 1JJ

 

Intellectual Property Solicitors

Appleyard Lees

The Lexicon

Mount Street

Manchester

M2 5NT

 

Registrars

Share Registrars Limited

9 Lion and Lamb Yard

Farnham

GU9 7LL

OptiBiotix Health plc Timeline

View All

Columns Including OPTI

VIEW ALL

Market Reports Including OPTI

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.